Acute Myeloid Leukemia (AML) With

specific

Acute myeloid leukemia characterized by the presence of a FLT3-internal tandem duplication (ITD) mutation. Patients with this mutation usually present with more aggressive disease and have higher rates of relapse after remission.

22

Centers

0

Active Trials

$4M

Cancer Funding

Top Centers for Acute Myeloid Leukemia (AML) With(22)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
Active Research Program
69.0
2
NCI Comprehensive
Active Research Program
67.4
3
NCI Comprehensive
50.7
4
NCI Comprehensive
50.7
5
NCI Comprehensive
50.7
6
NCI Comprehensive
50.7
7
NCI Comprehensive
50.7
8
NCI Clinical
50.7
9
NCI Comprehensive
50.7
10
NCI Comprehensive
50.7
1150.7
1250.7
1350.7
14
NCI Comprehensive
50.7
1550.7
1650.7
1750.7
1850.7
1950.7
2050.7
2150.7
2250.7

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →